Bisphosphonate-Related Osteonecrosis of the Jaws: A Single-Center Study of 101 Patients

Journal of Oral and Maxillofacial Surgery

Volumn 67, Issue 4, 2009, Pages 850-855

  Lazarovici, Towy Sorel ^a   Yahalom, Ran ^a   Taicher, Shlomo ^a   Elad, Sharon ^b   Hardan, Izhar ^a   Yarom, Noam ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMOXICILLIN; CLINDAMYCIN; CLODRONIC ACID; DEXAMETHASONE; DIURETIC AGENT; DOXYCYCLINE; INTERFERON; PAMIDRONIC ACID; PENICILLIN G; PREDNISONE; RISEDRONIC ACID; THALIDOMIDE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG INDICATION; DRUG USE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PATHOGENESIS; SMOKING HABIT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; ANGIOGENESIS INHIBITORS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BONE DENSITY CONSERVATION AGENTS; DIABETES MELLITUS, TYPE 2; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; JAW DISEASES; MALE; MIDDLE AGED; ORAL SURGICAL PROCEDURES; OSTEONECROSIS; RISK FACTORS; SMOKING; SURGICAL PROCEDURES, MINIMALLY INVASIVE; TIME FACTORS; TREATMENT OUTCOME; WOUND HEALING;

EID: 62649163689     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2008.11.015     Document Type: Article

References (32)

1. Rogers M.J., Watts D.J., and Russell R.G. Overview of bisphosphonates. Cancer 80 (1997) 1652
2. Body J.J., Lortholary A., Romieu G., et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res 14 (1999) 1557
3. Boissier S., Ferreras M., Peyruchaud O., et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60 (2000) 2949
4. Jantunen E. Bisphosphonate therapy in multiple myeloma: Past, present, future. Eur J Haematol 6 (2002) 257
5. Glover D., Lipton A., Keller A., et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer 74 (1994) 2949
6. Lipton A. Zoledronate in the treatment of osteolytic bone metastases. Br J Clin Pract Suppl 87 (1996)
7. Clézardin P. The antitumor potential of bisphosphonates. Semin Oncol 29 (2002) 33
8. Kanis J.A., Gertz B.J., Singer F., et al. Rationale for the use of alendronate in osteoporosis. Osteoporos Int 5 (1995) 1
9. Hellstein J.W., and Marek C.L. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?. J Oral Maxillofac Surg 63 (2005) 682
10. Russell R.G., Watts N.B., Ebetino F.H., et al. Mechanisms of action of bisphosphonates: Similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19 (2008) 733
11. Allegra A., Oteri G., and Nastro E. Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Hematol Oncol 25 (2007) 164
12. Wang J., Goodger N.M., and Pogrel M.A. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61 (2003) 1104
13. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115
14. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527
15. Marx R.E., Sawatari Y., Fortin M., et al. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (2005) 1567
16. Durie B.G., Katz M., and Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353 (2005) 99
17. Elad S., Yarom N., Hamed W., et al. Osteomyelitis and necrosis of the jaw in patients treated with bisphosphonates: A comparative study focused on multiple myeloma. Clin Lab Haematol 28 (2006) 393
18. Migliorati C.A., Casiglia J., Epstein J., et al. Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper. J Am Dent Assoc 136 (2005) 1658
19. Wang E.P., Kaban L.B., Strewler G.J., et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 65 (2007) 1328
20. Migliorati C.A., Schubert M.M., Peterson D.E., et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer 104 (2005) 83
21. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 (2007) 369
22. Mavrokokki T., Cheng A., Stein B., et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 (2007) 415
23. Abu-Id M.H., Warnke P.H., Gottschalk J., et al. "Bis-phossy jaws"-High and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. J Craniomaxillofac Surg 36 (2008) 95
24. Khamaisi M., Regev E., Yarom N., et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 92 (2007) 1172
25. Favus M.J. Diabetes and the risk of osteonecrosis of the jaw. J Clin Endocrinol Metab 92 (2007) 817
26. Varas-Lorenzo C., Rueda de Castro A.M., Maguire A., et al. Prevalence of glucose metabolism abnormalities and cardiovascular co-morbidity in the US elderly adult population. Pharmacoepidemiol Drug Saf 15 (2006) 317
27. Forouhi N.G., Merrick D., Goyder E., et al. Diabetes prevalence in England, 2001-Estimates from an epidemiological model. Diabet Med 23 (2006) 189
28. Szeto C.C., and Chow K.M. Nephrotoxicity related to new therapeutic compounds. Ren Fail 27 (2005) 329
29. Zervas K., Verrou E., Teleioudis Z., et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. Br J Haematol 134 (2006) 620
30. Smith D.W. Is avascular necrosis of the femoral head the result of inhibition of angiogenesis?. Med Hypotheses 49 (1997) 497
31. Marx R.E., Cillo Jr. J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65 (2007) 2397
32. Hansen T., Kunkel M., Springer E., et al. Actinomycosis of the jaws-Histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 451 (2007) 1009